Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

The green light means that Kisqali is now available “in multiple indications through the NHS which, coupled with the recent ASCO data demonstrating increased survival for pre-menopausal women ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

“This study, along with the PATRICIA subgroup analysis reported at ASCO 2024, support a paradigm shift toward considering ...